Allianz Asset Management GmbH Acquires New Position in ICU Medical, Inc. $ICUI

Allianz Asset Management GmbH acquired a new stake in shares of ICU Medical, Inc. (NASDAQ:ICUI) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 32,506 shares of the medical instruments supplier’s stock, valued at approximately $4,296,000. Allianz Asset Management GmbH owned approximately 0.13% of ICU Medical at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of ICUI. GAMMA Investing LLC grew its stake in ICU Medical by 27.2% during the 1st quarter. GAMMA Investing LLC now owns 716 shares of the medical instruments supplier’s stock valued at $99,000 after acquiring an additional 153 shares in the last quarter. Blue Trust Inc. grew its stake in ICU Medical by 23.0% during the 1st quarter. Blue Trust Inc. now owns 801 shares of the medical instruments supplier’s stock valued at $111,000 after acquiring an additional 150 shares in the last quarter. Vontobel Holding Ltd. purchased a new stake in ICU Medical during the 1st quarter valued at about $235,000. Principal Financial Group Inc. grew its stake in ICU Medical by 3.0% during the 1st quarter. Principal Financial Group Inc. now owns 136,009 shares of the medical instruments supplier’s stock valued at $18,886,000 after acquiring an additional 3,910 shares in the last quarter. Finally, Envestnet Asset Management Inc. grew its stake in ICU Medical by 8.2% during the 1st quarter. Envestnet Asset Management Inc. now owns 20,269 shares of the medical instruments supplier’s stock valued at $2,815,000 after acquiring an additional 1,534 shares in the last quarter. Hedge funds and other institutional investors own 96.10% of the company’s stock.

ICU Medical Stock Down 0.6%

Shares of NASDAQ ICUI opened at $121.67 on Friday. The company has a 50 day simple moving average of $124.21 and a 200-day simple moving average of $129.51. The company has a market capitalization of $3.00 billion, a P/E ratio of -80.05 and a beta of 0.83. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.44 and a quick ratio of 1.17. ICU Medical, Inc. has a 1 year low of $107.00 and a 1 year high of $196.26.

ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $2.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.44 by $0.66. The business had revenue of $543.57 million during the quarter, compared to the consensus estimate of $543.33 million. ICU Medical had a negative net margin of 1.56% and a positive return on equity of 7.24%. The business’s revenue was down 8.0% compared to the same quarter last year. During the same quarter last year, the firm earned $1.56 EPS. ICU Medical has set its FY 2025 guidance at 6.850-7.15 EPS. On average, equities research analysts predict that ICU Medical, Inc. will post 4.11 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts recently issued reports on the stock. Piper Sandler upped their price objective on shares of ICU Medical from $145.00 to $153.00 and gave the company an “overweight” rating in a research note on Wednesday, September 10th. Wall Street Zen raised shares of ICU Medical from a “hold” rating to a “buy” rating in a research note on Friday, September 5th. Weiss Ratings restated a “sell (d-)” rating on shares of ICU Medical in a report on Wednesday, October 8th. KeyCorp cut their price target on shares of ICU Medical from $191.00 to $173.00 and set an “overweight” rating for the company in a report on Tuesday. Finally, Raymond James Financial cut their price target on shares of ICU Medical from $187.00 to $180.00 and set a “strong-buy” rating for the company in a report on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, ICU Medical presently has an average rating of “Moderate Buy” and an average price target of $176.50.

Insider Buying and Selling

In related news, Director David C. Greenberg acquired 1,200 shares of the stock in a transaction that occurred on Wednesday, August 27th. The stock was purchased at an average price of $126.42 per share, with a total value of $151,704.00. Following the transaction, the director owned 7,960 shares of the company’s stock, valued at approximately $1,006,303.20. This trade represents a 17.75% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Vivek Jain acquired 21,929 shares of the stock in a transaction that occurred on Thursday, August 14th. The shares were bought at an average cost of $112.84 per share, with a total value of $2,474,468.36. Following the transaction, the chief executive officer directly owned 130,149 shares in the company, valued at $14,686,013.16. This trade represents a 20.26% increase in their position. The disclosure for this purchase can be found here. Company insiders own 1.50% of the company’s stock.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.